Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Clinical trial NCT02269592 · RECRUITING

Trial details

NCT number: NCT02269592
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Study type: OBSERVATIONAL

Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic Syndromes Hematological Malignancies B-cell Malignancy, Low-grade Myelodysplastic Syndrome With Low-grade Lesions IgG Monoclonal Gammopathy of Uncertain Significance Smoldering Multiple Myeloma Waldenstrom Macroglobulinemia

Start date: 2014-08-01
Primary completion: 2027-12-01
Enrollment: 10000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.